Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-BA-9 in Advanced Clear Cell Renal Cell Carcinoma
NCT07865832Phase 1Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CM-BA-9 in clear cell renal cell carcinoma (ccRCC). Primary endpoints: Safety and tolerability of CM-BA-9 at 52 weeks and Feasibility of CM-BA-9 manufacturing and administration. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CM-BA-9
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07865832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07865832.